Westfield Capital Management Co. LP Decreases Stock Position in Soleno Therapeutics, Inc. $SLNO

Westfield Capital Management Co. LP lessened its stake in shares of Soleno Therapeutics, Inc. (NASDAQ:SLNO) by 37.1% in the 3rd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 899,157 shares of the company’s stock after selling 530,599 shares during the period. Westfield Capital Management Co. LP’s holdings in Soleno Therapeutics were worth $60,783,000 as of its most recent filing with the Securities & Exchange Commission.

Several other large investors have also recently made changes to their positions in the company. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its stake in Soleno Therapeutics by 1.1% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 17,360 shares of the company’s stock valued at $1,242,000 after buying an additional 189 shares during the last quarter. Goldman Sachs Group Inc. raised its holdings in shares of Soleno Therapeutics by 50.9% during the 1st quarter. Goldman Sachs Group Inc. now owns 633,110 shares of the company’s stock worth $45,236,000 after acquiring an additional 213,667 shares in the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC boosted its position in shares of Soleno Therapeutics by 48.0% during the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 40,715 shares of the company’s stock valued at $2,909,000 after acquiring an additional 13,211 shares during the last quarter. Nisa Investment Advisors LLC grew its holdings in shares of Soleno Therapeutics by 287.8% in the second quarter. Nisa Investment Advisors LLC now owns 539 shares of the company’s stock valued at $45,000 after purchasing an additional 400 shares in the last quarter. Finally, Envestnet Asset Management Inc. grew its holdings in shares of Soleno Therapeutics by 32.9% in the second quarter. Envestnet Asset Management Inc. now owns 5,866 shares of the company’s stock valued at $491,000 after purchasing an additional 1,453 shares in the last quarter. 97.42% of the stock is owned by institutional investors.

Analysts Set New Price Targets

SLNO has been the topic of a number of recent research reports. Wolfe Research set a $60.00 price target on shares of Soleno Therapeutics in a research note on Monday, January 12th. Wall Street Zen upgraded shares of Soleno Therapeutics from a “hold” rating to a “buy” rating in a report on Saturday, November 8th. Wells Fargo & Company reaffirmed an “overweight” rating and issued a $114.00 price target (up from $106.00) on shares of Soleno Therapeutics in a report on Tuesday, January 20th. Robert W. Baird set a $107.00 price objective on Soleno Therapeutics in a research note on Tuesday, January 13th. Finally, Zacks Research downgraded Soleno Therapeutics from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, February 3rd. One equities research analyst has rated the stock with a Strong Buy rating, twelve have given a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $108.69.

Soleno Therapeutics Stock Performance

Shares of NASDAQ:SLNO opened at $38.09 on Friday. The company has a market capitalization of $2.05 billion, a price-to-earnings ratio of 165.62 and a beta of -3.16. Soleno Therapeutics, Inc. has a 12 month low of $32.63 and a 12 month high of $90.32. The firm’s 50-day moving average is $42.80 and its 200 day moving average is $53.86. The company has a current ratio of 16.08, a quick ratio of 15.88 and a debt-to-equity ratio of 0.10.

Soleno Therapeutics (NASDAQ:SLNO) last announced its quarterly earnings data on Wednesday, February 25th. The company reported $0.80 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.64 by $0.16. The firm had revenue of $91.73 million during the quarter, compared to the consensus estimate of $88.55 million. Research analysts predict that Soleno Therapeutics, Inc. will post -3.72 EPS for the current year.

Soleno Therapeutics Company Profile

Soleno Therapeutics, Inc is a clinical‐stage biopharmaceutical company focused on the development and commercialization of therapies for rare and orphan diseases. Headquartered in Redwood City, California, Soleno leverages a precision medicine approach to identify and advance small‐molecule treatments that address underlying genetic and metabolic dysfunctions. The company’s scientific strategy centers on repurposing and reformulating existing compounds to maximize therapeutic benefit in underserved patient populations.

The company’s lead candidate, diazoxide choline controlled release (DCCR), is being investigated for the treatment of Prader-Willi syndrome (PWS), a complex neurodevelopmental disorder characterized by insatiable appetite, hormonal imbalances and behavioral challenges.